05:59 AM EDT, 06/02/2025 (MT Newswires) -- Novartis ( NVS ) said Monday that its radioligand therapy, Pluvicto, combined with standard care, significantly improved radiographic progression-free survival in a pre-specified interim analysis of a phase 3 trial for patients with a certain type of prostate cancer.
The drugmaker said a positive trend in overall survival was also observed.